Project I.D.E.F.I.X – EIC Transition 2022

Cherry_Biotech-CubiX-IDEFIX-project

Project I.D.E.F.I.X – EIC Transition 2022

I.D.E.F.I.X project, a Multiorgan Toxicity and Efficacy Test Platform as a New Standard as an Alternative to Animal Experimentation

Objectives

Our role

As project sole partner and leader, Cherry Biotech will implement the project. The IDEFIX project will run for 30 months to further develop, integrate, and validate the new microfluidic IDEFIX modular platform with external KOL partners. Divided into 4 interconnected work packages, its pathway to deployment is briefly described thereafter

Expected Results

Differentiated endothelium in 3D culture
Differentiated endothelium in 3D culture
Organoids from metastatic breast cancer
Organoids from metastatic breast cancer

Managing team

Jeremy Cramer - Founder & CEO
Jeremy Cramer
 

WP1 Platform Maturity Development

Dario Fassini

 

WP2 Biological Validation and Qualification

WP3 - Go-to market & business strategy
Jeremy Cramer
Pierre Gaudriault

WP3 Go-to Market and Business Strategy
Pierre Gaudriault

Pierre Gaudriault 

 

WP4 Global Project Coordinator

This project has been funded by The European Union, under the grant agreement n° 101099775.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

start a project with us

Our expertise combines Microfluidic, 3DCell culture, Microscopy, Omics and artificial intelligence.
Let’s get intouch to see how we can collaborate for future projects

As part of our commercial prospecting, we may need to process your personal data. For more information, please consult our Privacy Policy